{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05356182",
            "orgStudyIdInfo": {
                "id": "STUDY00005755"
            },
            "organization": {
                "fullName": "State University of New York at Buffalo",
                "class": "OTHER"
            },
            "briefTitle": "A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies",
            "officialTitle": "A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-pilot-and-feasibility-study-of-a-dietary-intervention-with-low-protein-meals-in-cancer-patients-receiving-immunotherapies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-05-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-04-01",
            "studyFirstSubmitQcDate": "2022-04-29",
            "studyFirstPostDateStruct": {
                "date": "2022-05-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-21",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Roberto Pili",
                "investigatorTitle": "Associate Dean for Cancer Research and Integrative Oncology",
                "investigatorAffiliation": "State University of New York at Buffalo"
            },
            "leadSponsor": {
                "name": "State University of New York at Buffalo",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main idea of this study is that a low protein diet may alter the environment surrounding the tumor, enhancing the body's immune response leading to greater anticancer effects of treatment. This study intends to use a low-protein diet as a tool to enhance the immune response generated by immune check point inhibitor treatments.",
            "detailedDescription": "This is a single center, randomized, open label study to assess the feasibility of a low-protein diet intervention in cancer patients who are receiving immunotherapies. Subjects will be randomized in a 1:1 ratio to either immunotherapy plus control diet arm (\\~20% protein content) or immunotherapy plus intervention low-protein diet arm (10% protein content)."
        },
        "conditionsModule": {
            "conditions": [
                "Medical Oncology",
                "Integrative Oncology",
                "Medical Nutrition Therapy"
            ],
            "keywords": [
                "Oncology",
                "Nutrition",
                "Immunotherapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Control Diet Arm",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "control diet arm (\\~20% protein content)",
                    "interventionNames": [
                        "Other: Diet"
                    ]
                },
                {
                    "label": "Low-Protein Diet Arm",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "intervention low-protein diet arm (10% protein content)",
                    "interventionNames": [
                        "Other: Diet"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Diet",
                    "description": "Control diet consisting of 20% protein, intervention diet consisting of 10% protein",
                    "armGroupLabels": [
                        "Control Diet Arm",
                        "Low-Protein Diet Arm"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "To assess the feasibility of low-protein diet intervention in cancer patients receiving immunotherapies.",
                    "description": "Change in blood urea nitrogen (BUN) from baseline to post-intervention (following 3 cycles of treatment) will be measured to assess adherence of following the diet intervention.",
                    "timeFrame": "4 Months"
                },
                {
                    "measure": "To assess the feasibility of low-protein diet intervention in cancer patients receiving immunotherapies.",
                    "description": "Change in urine urea nitrogen (UUN) from baseline to post-intervention (following 3 cycles of treatment) will be measured to assess adherence of following the diet intervention.",
                    "timeFrame": "4 Months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To assess whether low-protein diet intervention augments the immune response to immunotherapies in cancer patients receiving immunotherapies",
                    "description": "Includes isolation and characterization of antigen specific T cell clones",
                    "timeFrame": "4 Months"
                },
                {
                    "measure": "To assess whether low-protein diet intervention augments the immune response to immunotherapies in cancer patients receiving immunotherapies",
                    "description": "Includes evaluation of antigen specific T cell populations by spectratyping T cell receptor expression",
                    "timeFrame": "4 Months"
                },
                {
                    "measure": "To assess whether low-protein diet intervention augments the immune response to immunotherapies in cancer patients receiving immunotherapies",
                    "description": "Includes characterization of antigen response by cytokine and chemokine production",
                    "timeFrame": "4 Months"
                },
                {
                    "measure": "To assess the enrollment rate (safety and tolerability) of the combination of immunotherapies and low-protein diet intervention",
                    "description": "Enrollment rate",
                    "timeFrame": "4 Months"
                },
                {
                    "measure": "To assess the Drop-out rate (safety and tolerability) of the combination of immunotherapies and low-protein diet intervention",
                    "description": "Drop-out rate",
                    "timeFrame": "4 Months"
                },
                {
                    "measure": "To assess the safety and tolerability of the combination of immunotherapies and low-protein diet intervention",
                    "description": "Compliance with diet measured by self-report of patient",
                    "timeFrame": "4 Months"
                },
                {
                    "measure": "To obtain preliminary evidence of clinical efficacy of immunotherapies and low-protein diet compared to immunotherapies and control-diet using the RECIST v1.1 criteria",
                    "description": "Objective Response Rate (ORR)",
                    "timeFrame": "4 Months"
                },
                {
                    "measure": "To obtain preliminary evidence of clinical efficacy of immunotherapies and low-protein diet compared to immunotherapies and control-diet using the RECIST v1.1 criteria",
                    "description": "Progression-Free Survival (PFS)",
                    "timeFrame": "4 Months"
                },
                {
                    "measure": "To obtain preliminary evidence of clinical efficacy of immunotherapies and low-protein diet compared to immunotherapies and control-diet using the RECIST v1.1 criteria",
                    "description": "Overall Survival(OS)",
                    "timeFrame": "4 Months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically documented solid tumor malignancies which is amenable for immunotherapy treatment with immune checkpoint inhibitors (i.e. PD1, PD-L1, CTLA inhibitors) as single agents or in combination.\n* Metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (CT) scan of the chest, abdomen, and pelvis\n* Life expectancy of at least 6 months\n* Adults \u2265 18 years of age\n* Adequate hematologic, renal, and liver function as evidenced by the following:\n\n  * White blood cell (WBC) \u2265 2,500 cells/\u03bcL\n  * Absolute neutrophil count (ANC) \u2265 1,000 cells/\u03bcL\n  * Platelet Count \u2265 100,000 cells/\u03bcL\n  * Hemoglobin (HgB) \u2265 9.0 g/dL\n  * Creatinine \u2264 2.0 mg/dL\n  * Total bilirubin \u2264 2 x upper limit of normal (ULN)\n  * Aspartate aminotransaminase (AST, SGOT) \u2264 2.5 x ULN\n  * Alanine aminotransaminase (ALT, SGPT) \u2264 2.5 x ULN\n\nExclusion Criteria:\n\n* \u2022 Eastern Cooperative Oncology Group (ECOG) performance status 2 or higher\n\n  * Treatment with any of the following medications or interventions within 28 days of registration:\n\n    * Systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable.\n    * High dose calcitriol \\[1,25(OH)2VitD\\] (i.e., \\> 7.0 \u03bcg/week)\n  * A requirement for systemic immunosuppressive therapy for any reason\n  * Any infection requiring parenteral antibiotic therapy or causing fever (temperature \\> 100.5\u00b0F or 38.1\u00b0C) within 1 week prior to registration\n  * A known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT imaging\n  * Any medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "locations": [
                {
                    "facility": "University at Buffalo / Great Lakes Cancer Care",
                    "status": "RECRUITING",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ashlee Lang, MPH",
                            "role": "CONTACT",
                            "phone": "716-860-0267",
                            "email": "alang@kaleidahealth.org"
                        },
                        {
                            "name": "Kyle Pasquariello, MA",
                            "role": "CONTACT",
                            "phone": "716-529-6470",
                            "email": "kpasquariello@gppconline.com"
                        },
                        {
                            "name": "Roberto Pili, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED",
            "description": "undecided"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}